In addition, gefitinib, an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is the first approved targeting drug for the treatment of non-small cell lung cancer (NSCLC) [15]. Here, EGFR is linked to non-small cell lung carcinoma.